Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SPR | P35270 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27681335 | 0.86 | MAPK14 (0.50) | MYCNPC1RAB9AKMT2ALMNA | |
| SCHEMBL28764836 | 0.86 | MYC (0.48) | MYCNPC1RAB9AKMT2ALMNA | |
| SCHEMBL16166020 | 0.85 | MAPT (0.54) | MAPK1NPC1RAB9APKMSPR | |
| SCHEMBL13184688 | 0.82 | MAPK14 (0.55) | MYCMAPK1GAASLC9A1MAPT | |
| SCHEMBL21605010 | 0.82 | MAPT (0.59) | MYCNPC1RAB9AKMT2AKDM4E | |
| SCHEMBL14692559 | 0.80 | MAPK1 (0.41) | MYCMAPK1NPC1RAB9APKM | |
| SCHEMBL20604158 | 0.78 | MAPK1 (0.51) | MAPK1NPC1RAB9APKMSPR | |
| SCHEMBL3517338 | 0.78 | NPC1 (0.55) | MYCMAPK1NPC1RAB9ASPR | |
| SCHEMBL15167592 | 0.78 | SPR (0.47) | MAPK1NPC1RAB9APKMSPR | |
| SCHEMBL16166157 | 0.78 | KMT2A (0.47) | MAPK1NPC1RAB9ASPRNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV OF MARYLAND BALTIMORE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2025-08-05 | — | — | US | disclosed |
| EP-3423452-B1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIV MARYLAND (US) | 2025-05-07 | — | — | EP | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2024-06-27 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2023-05-23 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-01-05 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-10723715-B2 | — | — | 2020-07-28 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | UNIVERSITY OF MARYLAND, BALTIMORE | 2019-03-07 | — | — | US | disclosed |
| EP-3423452-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | University of Maryland, Baltimore (US) | 2019-01-09 | — | — | EP | disclosed |
| US-9750253-B2 | Pesticidally active substituted pyridyl carboxamides | SYNGENTA PARTICIPATIONS AG (CH) | 2017-09-05 | — | — | US | disclosed |
| EP-2984083-B1 | PESTICIDALLY ACTIVE SUBSTITUTED PYRIDYL CARBOXAMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-01-25 | — | — | EP | disclosed |
| US-20160050924-A1 | PESTICIDALLY ACTIVE SUBSTITUTED PYRIDYL CARBOXAMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2016-02-25 | — | — | US | disclosed |
| EP-2984083-A1 | PESTICIDALLY ACTIVE SUBSTITUTED PYRIDYL CARBOXAMIDES | Syngenta Participations AG (CH) | 2016-02-17 | — | — | EP | disclosed |
| WO-2014166795-A1 | PESTICIDALLY ACTIVE SUBSTITUTED PYRIDYL CARBOXAMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882841-B2 | Wnt signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MYC 92/4885MAPK1 141/4885NPC1 301/4885 |
| US-12378220-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MYC 92/4885MAPK1 141/4885NPC1 301/4885 |
| US-20160050924-A1 | PESTICIDALLY ACTIVE SUBSTITUTED PYRIDYL CARBOXAMIDES | CBR3, CBR1, CYCS | MYC 2404/4885MAPK1 1509/4885NPC1 3544/4885 |
| US-20190071424-A1 | WNT Signaling Pathway Inhibitors for Treatments of Disease | WNT1, CTNNB1, WNT3A | MYC 92/4885MAPK1 141/4885NPC1 301/4885 |
| US-11655233-B2 | WNT signaling pathway inhibitors for treatments of disease | WNT1, CTNNB1, WNT3A | MYC 92/4885MAPK1 141/4885NPC1 301/4885 |
| US-20260138966-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | CTNNB1, WNT1, CTNND1 | MYC 99/4885MAPK1 475/4885NPC1 598/4885 |
| US-20240208927-A1 | WNT SIGNALING PATHWAY INHIBITORS FOR TREATMENTS OF DISEASE | WNT1, CTNNB1, WNT3A | MYC 92/4885MAPK1 141/4885NPC1 301/4885 |
| US-10723715-B2 | — | CTNNB1, WNT1, CTNNBL1 | MYC 16/4885MAPK1 1136/4885NPC1 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.